BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts

On November 10, 2025, BMO Capital reiterated its “Outperform” standing connected Structure Therapeutics Inc. (NASDAQ:GPCR), mounting a $100 terms target. The steadfast cited upcoming ACCESS I and II Phase 2b obesity proceedings readouts, believing they could bolster the company’s competitory presumption successful the weight-loss cause market. The concern steadfast highlighted easing expectations pursuing Eli Lilly’s caller data, which makes Structure’s results a important benchmark.

Meanwhile, Structure Therapeutics Inc. (NASDAQ:GPCR) reported its Q3 2025 results connected November 6. The 4th saw the institution reaffirm that its ongoing obesity studies stay connected way for year-end. In the quarter, the institution besides noted advancement connected its oral amylin receptor agonist programs. However, probe costs came retired high, reaching $59 million, which the institution expects to stay elevated owed to upcoming proceedings spending. The nett nonaccomplishment widened to $65.7 million, compared to $34 cardinal successful Q3 2024.

Structure Therapeutics Inc. (NASDAQ:GPCR) ended the 4th with a beardown currency presumption of $799 million, which volition enactment the company’s continued improvement and planned survey initiations done 2026.

Structure Therapeutics Inc. (NASDAQ:GPCR), a biopharmaceutical company, develops oral small-molecule treatments for metabolic diseases.

While we admit the imaginable of GPCR arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.

Disclosure: None.